RCAMU
ICPT

Rothschild & Co Asset Management US’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Rothschild & Co Asset Management US’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-221,611
Closed -$9.19M – 318
2020
Q3 		$9.19M Sell
221,611
-39,229
-15% -$1.8M 0.17% 202
2020
Q2 		$12.5M Buy
+260,840
New +$20.2M 0.18% 195

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Rothschild & Co Asset Management US's ICPT Position: Q4 2020 in Review

Rothschild & Co Asset Management US sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2020, closing a stake of 221,611 shares — an estimated $9.19M sold.

Rothschild & Co Asset Management US first reported a position in ICPT in Q2 2020 and held it in 2 quarters. The position peaked at $12.5M in Q2 2020. 175 funds tracked by Wall St. Rank hold ICPT as of Q4 2020.

  • Rothschild & Co Asset Management US reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2020 after selling out during the quarter.
  • Rothschild & Co Asset Management US sold 221,611 Intercept Pharmaceuticals, Inc. shares in Q4 2020, an estimated $9.19M.
  • Rothschild & Co Asset Management US first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2020 and held it in 2 quarters.
  • Rothschild & Co Asset Management US's Intercept Pharmaceuticals, Inc. position peaked at $12.5M in Q2 2020.
  • 175 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2020.

Based on Rothschild & Co Asset Management US's 13F filing for Q4 2020, filed 8 Feb 2021.